Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Esteban Celis

Showing results (71-80 of 121) with videos related to

Pageof 13
Sort By:
Cancer Immunology, Immunotherapy : CII|October 23, 2008
Focal adhesion kinase as an immunotherapeutic targetHiroya Kobayashi, Makoto Azumi, Yuka Kimura, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2015
CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphomaTakumi Kumai, Toshihiro Nagato, Hiroya Kobayashi, et al.
Cancer Research|February 5, 2008
Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cellsHiroya Kobayashi, Toshihiro Nagato, Miki Takahara, et al.
Oncoimmunology|May 8, 2015
c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphomaTakumi Kumai, Yoshinari Matsuda, Takayuki Ohkuri, et al.
Scientific Reports|November 6, 2015
Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinomaTakumi Kumai, Takayuki Ohkuri, Toshihiro Nagato, et al.
The Journal of Clinical Investigation|March 18, 2010
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in miceRupal Ramakrishnan, Deepak Assudani, Srinivas Nagaraj, et al.
Journal of Translational Medicine|November 8, 2011
Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancerSatoshi Hayashi, Takumi Kumai, Yoshiya Matsuda, et al.
Oncotarget|March 24, 2016
T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapyPatrick L Raber, Rosa A Sierra, Paul T Thevenot, et al.
Cancer Immunology Research|February 28, 2018
Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 InhibitionHussein Sultan, Takumi Kumai, Valentyna I Fesenkova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacementsEduardo Huarte, Pablo Sarobe, Jun Lu, et al.
Pageof 13

Showing results (71-80 of 121) with videos related to

Sort By:
Pageof 13
Cancer Immunology, Immunotherapy : CII|October 23, 2008
Focal adhesion kinase as an immunotherapeutic targetHiroya Kobayashi, Makoto Azumi, Yuka Kimura, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2015
CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphomaTakumi Kumai, Toshihiro Nagato, Hiroya Kobayashi, et al.
Cancer Research|February 5, 2008
Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cellsHiroya Kobayashi, Toshihiro Nagato, Miki Takahara, et al.
Oncoimmunology|May 8, 2015
c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphomaTakumi Kumai, Yoshinari Matsuda, Takayuki Ohkuri, et al.
Scientific Reports|November 6, 2015
Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinomaTakumi Kumai, Takayuki Ohkuri, Toshihiro Nagato, et al.
The Journal of Clinical Investigation|March 18, 2010
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in miceRupal Ramakrishnan, Deepak Assudani, Srinivas Nagaraj, et al.
Journal of Translational Medicine|November 8, 2011
Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancerSatoshi Hayashi, Takumi Kumai, Yoshiya Matsuda, et al.
Oncotarget|March 24, 2016
T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapyPatrick L Raber, Rosa A Sierra, Paul T Thevenot, et al.
Cancer Immunology Research|February 28, 2018
Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 InhibitionHussein Sultan, Takumi Kumai, Valentyna I Fesenkova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacementsEduardo Huarte, Pablo Sarobe, Jun Lu, et al.
Pageof 13